Isotonitazene: Isotonitazene (CAS 14188-81-9) was first characterized in illicit markets in 2019 and scheduled by the U.S. DEA in 2020. In vitro it shows sub-nanomolar MOR efficacy and produces more prolonged respiratory depression than equipotent fentanyl. Community users warn that Narcan may need
Related pages